Risk Factors for Systemic Inflammatory Response Syndrome After Percutaneous Transhepatic Cholangioscopic Lithotripsy
Lve Cheng,Junwei Niu,Yao Cheng,Jie Liu,Mengjia Shi,Shijia Huang,Xiong Ding,Shengwei Li
DOI: https://doi.org/10.2147/jir.s453653
IF: 4.5
2024-04-26
Journal of Inflammation Research
Abstract:Lve Cheng, &ast Junwei Niu, &ast Yao Cheng, &ast Jie Liu, Mengjia Shi, Shijia Huang, Xiong Ding, Shengwei Li Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiong Ding; Shengwei Li, Department of Hepatobiliary Surgery, Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong, Chongqing, 400010, People's Republic of China, Tel +86-13677662766 ; +86-13508312245, Email ; Background: There is a lack of validated predictive models for the occurrence of systemic inflammatory response syndrome (SIRS) after percutaneous transhepatic cholangioscopic lithotripsy (PTCSL) for the treatment of hepatolithiasis. This is the first study to estimate the incidence of SIRS after PTCSL. Methods: A retrospective analysis of 284 PTCSL sessions for the treatment of hepatolithiasis at our institution between January 2019 and January 2023 was performed. The development of SIRS after PTCSL was the primary study endpoint. Independent risk factors for SIRS after PTCSL were identified using univariate and multivariate logistic regression analyses. A nomogram prediction model was constructed using these independent risk factors, and the predictive value was assessed using receiver operating characteristic (ROC) curves. Results: The incidence of SIRS after PTCSL was 20.77%. According to multivariate analysis, the number of PTCSL sessions (odds ratio [OR]=0.399, 95% confidence interval [CI]=0.202– 0.786, p=0.008), stone location (OR=2.194, 95% CI=1.107– 4.347, p=0.024), intraoperative use of norepinephrine (OR=0.301, 95% CI=0.131– 0.689, p=0.004), intraoperative puncture (OR=3.476, 95% CI=1.749– 6.906, P< 0.001), preoperative gamma-glutamyltransferase (OR=1.002, 95% CI=1.001– 1.004, p=0.009), and preoperative total lymphocyte count (OR=1.820, 95% CI=1.110– 2.985, p=0.018) were found to be independent risk factors for the development of SIRS after PTCSL. These six independent risk factors were used to construct a nomogram prediction model, which showed satisfactory accuracy with an area under the ROC curve of 0.776 (95% CI: 0.702– 0.850). Conclusion: The number of PTCSL sessions, stone location, intraoperative use of norepinephrine, intraoperative puncture, preoperative gamma-glutamyltransferase, and preoperative total lymphocyte count may predict the occurrence of SIRS after PTCSL. This prediction model may help clinicians identify high-risk patients in advance. Keywords: percutaneous transhepatic cholangioscopic lithotripsy, hepatolithiasis, systemic inflammatory response syndrome, risk factors, nomogram Hepatolithiasis is a common benign disease of the biliary tract in Southeast Asia. 1,2 It is the leading cause of death from nonneoplastic biliary disease. 1,2 The prolonged presence of stones can lead to biliary sepsis, biliary cirrhosis, and cholangiocarcinoma. 1,2 However, due to the complexity of the anatomy of the bile ducts and the specificity of the location of these stones, there is a high rate of stone retention and recurrence after hepatectomy. 3–5 It has been reported that 10–15% of cases of hepatolithiasis cannot be completely resolved by surgery. 6,7 If a patient has a recurrence of a stone and is in need of further surgery, the procedure is difficult, risky and has a long recovery time. 8 Therefore, a safe and reproducible minimally invasive surgical procedure to is needed to overcome the shortcomings of traditional surgeries. Percutaneous transhepatic cholangioscopic lithotripsy (PTCSL) is derived from percutaneous nephrolithiasis. 9–11 PTCSL has gradually become one of the most important tools used to treat hepatolithiasis. PTCSL is a less invasive treatment than traditional surgery and can preserve more liver parenchyma to maintain liver function. It is particularly suitable for patients who have a history of biliary surgery or scattered stones and who cannot tolerate traditional surgery. 12 Despite adequate preoperative preparation, PTCSL, as an invasive technique, is inevitably associated with surgical risks and complications. Although PTCSL has a low rate of postoperative complications, infection-related complications such as fever, systemic inflammatory response syndrome (SIRS), and sepsis may still occur postoperatively. 13–15 Intraoperative PTCSL may damage bile duct cells. As a consequence, large numbers of bacteria and endotoxins are released into the blood circulation. Biliary hypertension caused by prolonged biliary flushing can increase the absorption of pathogens with the perfusate and cause an -Abstract Truncated-
immunology